# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-18-016080
Filing Date
2018-11-16
Accepted
2018-11-16 17:00:41
Documents
10
Period of Report
2018-12-18
Effectiveness Date
2018-11-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRELIMINARY PROXY STATEMENT | def14a1118_actiniumpharma.htm | DEF 14A | 505224
2 | GRAPHIC | image_001.jpg | GRAPHIC | 25910
3 | GRAPHIC | image_002.jpg | GRAPHIC | 4265
4 | GRAPHIC | image_003.jpg | GRAPHIC | 44582
5 | GRAPHIC | image_004.jpg | GRAPHIC | 16282
6 | GRAPHIC | image_005.jpg | GRAPHIC | 19200
7 | GRAPHIC | image_006.jpg | GRAPHIC | 10519
8 | GRAPHIC | image_007.jpg | GRAPHIC | 21995
9 | GRAPHIC | proxy1.jpg | GRAPHIC | 204815
10 | GRAPHIC | proxy2.jpg | GRAPHIC | 255554
| Complete submission text file | 0001213900-18-016080.txt |  | 1338057

Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 181190474
SIC: 2834 Pharmaceutical Preparations